Innovative discovery of therapeutic, diagnostic, and antibody compositions related to protein fragments of aspartyl-tRNA synthetases

Patent metadata

Field	Value
Publication number	US-8969301-B2
Application number	US-201113809750-A
Country	US
Kind code	B2
Filing date	Jul 11, 2011
Priority date	Jul 12, 2010
Publication date	Mar 3, 2015
Grant date	Mar 3, 2015

Abstract

Provided are compositions comprising newly identified protein fragments of aminoacyl-tRNA synthetases, polynucleotides that encode them and complements thereof, related agents, and methods of use thereof in diagnostic, drug discovery, research, and therapeutic applications.

First claim

We claim:

1. A therapeutic composition, comprising an isolated aspartyl-tRNA synthetase (DRS) polypeptide of up to about 280 amino acids in length that comprises SEQ ID NO:16 or an amino acid sequence that is at least 95% identical to SEQ ID NO:16, wherein the polypeptide has an extracellular signaling activity and a solubility of at least about 5 mg/mL, and wherein the composition has a purity of at least about 95% on a protein basis and less than about 10 EU endotoxin/mg protein.

2. The therapeutic composition of claim 1 , wherein the DRS polypeptide specifically binds to a binding partner to exert a physiological effect.

3. The therapeutic composition of claim 1 , wherein the DRS polypeptide consists of SEQ ID NO:16 or differs from SEQ ID NO:16 by substitution, deletion, and/or addition of about 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, or 11 amino acids, and wherein the altered polypeptide retains an extracellular signaling activity of the unaltered polypeptide.

4. The therapeutic composition of claim 1 , wherein the DRS polypeptide is fused to a heterologous polypeptide.

5. The therapeutic composition of claim 1 , wherein at least one moiety or a solid substrate is covalently or non-covalently attached to said polypeptide.

6. The therapeutic composition of claim 1 , wherein the AARS polypeptide is fused to a pharmacokinetic (PK) property modifier.

7. The therapeutic composition of claim 3 , wherein the DRS polypeptide consists of SEQ ID NO:16 or differs from SEQ ID NO:16 by substitution, deletion, and/or addition of about 1, 2, 3, 4, or 5 amino acids.

8. The therapeutic composition of claim 1 , wherein the DRS polypeptide is up to about 240 amino acids in length and comprises SEQ ID NO:16 or a sequence that is at least 95% identical to SEQ ID NO:16.

9. The therapeutic composition of claim 8 , wherein the DRS polypeptide is up to about 240 amino acids in length and comprises SEQ ID NO:16.

10. The therapeutic composition of claim 1 , wherein the DRS polypeptide comprises SEQ ID NO:16 or 14.

Assignees

• Greene Leslie Ann
• Chiang Kyle P
• Hong Fei
• Vasserot Alain Philippe
• Lo Wing-Sze
• Watkins Jeffry D
• Quinn Cheryl L
• Mendlein John D
• Atyr Pharma Inc
• Pangu Biopharma Ltd

Inventors

• Greene Leslie Ann
• Chiang Kyle P
• Hong Fei
• Vasserot Alain Philippe
• Lo Wing-Sze
• Watkins Jeffry D
• Quinn Cheryl L
• Mendlein John D

Classifications

• A61P3/10

  for hyperglycaemia, e.g. antidiabetics · CPC title

• A61P7/00

  Drugs for disorders of the blood or the extracellular fluid · CPC title

• A61P9/14

  Vasoprotectives; Antihaemorrhoidals; Drugs for varicose therapy; Capillary stabilisers · CPC title

• A61P37/00

  Drugs for immunological or allergic disorders · CPC title

• A61P9/00

  Drugs for disorders of the cardiovascular system · CPC title